OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Key Highlights
- ➤OKYO Pharma (OKYO) will present at Eyecelerator on October 8, 2026
- ➤Global Phase 3 trial planned for second half of this year
- ➤Phase 3 trial expected to enroll approximately 111 NCP patients
- ➤Trial will evaluate single-dose urcosimod for neuropathic corneal pain
- ➤Leadership team will engage optometry and ophthalmology experts at upcoming meetings
Expert Statements
Robert J. Dempsey, Chief Executive Officer at OKYO Pharma
“Addressing Unmet Needs in Corneal and Anterior Segment Diseases”
* OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.
Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases Presentation Date/Time: Thursday, October 8, 2026, 1:29 PM CT Breakout: Anterior Segment, Room 243-245 Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma Moderators: Julie Schallhorn, MD, MS; Kendall Donaldson, MD
Get started
Create a free account to read the full story.